Targeting the Intestinal Microbiota: A Novel Direction in the Treatment of Inflammatory Bowel Disease

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Oct 26

PMID 39457652

Authors

Jie Zhang

Huilin Gan

Xiaoyan Duan

Guangming Li

Affiliations

Soon will be listed here.

Abstract

Over the past decade, there has been a rapid increase in the incidence of inflammatory bowel disease. It has been suggested that multifactorial interactions of environmental factors, genetic factors, immune response and intestinal microbiota are involved in the pathogenesis of inflammatory bowel disease. It is widely recognized that the intestinal microbiota are essential for human metabolism, the immune system and pathogen resistance, and are integral to human health. Therefore, the dysbiosis of the microbiota is a critical step leading to intestinal mucosal damage and a key factor in the pathogenesis of inflammatory bowel disease. Regulating the microbiota through interventions such as enteral nutrition, fecal microbiota transplantation, and probiotic supplementation has the potential to prevent or even reverse intestinal dysbiosis, opening up new perspectives for the treatment of inflammatory bowel disease.

References

Sugihara K, Kamada N . Diet-Microbiota Interactions in Inflammatory Bowel Disease. Nutrients. 2021; 13(5). PMC: 8147260. DOI: 10.3390/nu13051533. View

Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R . European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017; 66(4):569-580. PMC: 5529972. DOI: 10.1136/gutjnl-2016-313017. View

Lavelle A, Sokol H . Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020; 17(4):223-237. DOI: 10.1038/s41575-019-0258-z. View

Sicard J, Le Bihan G, Vogeleer P, Jacques M, Harel J . Interactions of Intestinal Bacteria with Components of the Intestinal Mucus. Front Cell Infect Microbiol. 2017; 7:387. PMC: 5591952. DOI: 10.3389/fcimb.2017.00387. View

Ding G, Yang X, Li Y, Wang Y, Du Y, Wang M . Gut microbiota regulates gut homeostasis, mucosal immunity and influences immune-related diseases. Mol Cell Biochem. 2024; . DOI: 10.1007/s11010-024-05077-y. View

Mann E, Lam Y, Uhlig H . Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024; 24(8):577-595. DOI: 10.1038/s41577-024-01014-8. View

Yao S, Zhao Z, Wang W, Liu X . Bifidobacterium Longum: Protection against Inflammatory Bowel Disease. J Immunol Res. 2021; 2021:8030297. PMC: 8324359. DOI: 10.1155/2021/8030297. View

Miyoshi J, Chang E . The gut microbiota and inflammatory bowel diseases. Transl Res. 2016; 179:38-48. PMC: 5156589. DOI: 10.1016/j.trsl.2016.06.002. View

Kang S, Lin Z, Xu Y, Park M, Ji G, Johnston T . A recombinant Bifidobacterium bifidum BGN4 strain expressing the streptococcal superoxide dismutase gene ameliorates inflammatory bowel disease. Microb Cell Fact. 2022; 21(1):113. PMC: 9172062. DOI: 10.1186/s12934-022-01840-2. View

10.

Henke M, Kenny D, Cassilly C, Vlamakis H, Xavier R, Clardy J . , a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci U S A. 2019; 116(26):12672-12677. PMC: 6601261. DOI: 10.1073/pnas.1904099116. View

11.

Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J . Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8(10):1179-207. DOI: 10.1016/j.crohns.2014.04.005. View

12.

Boger-May A, Reed T, LaTorre D, Ruley-Haase K, Hoffman H, English L . Altered microbial biogeography in an innate model of colitis. Gut Microbes. 2022; 14(1):2123677. PMC: 9519015. DOI: 10.1080/19490976.2022.2123677. View

13.

Vindigni S, Zisman T, Suskind D, Damman C . The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol. 2016; 9(4):606-25. PMC: 4913337. DOI: 10.1177/1756283X16644242. View

14.

Zhou L, Zhang M, Wang Y, Dorfman R, Liu H, Yu T . Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1. Inflamm Bowel Dis. 2018; 24(9):1926-1940. DOI: 10.1093/ibd/izy182. View

15.

Lu Q, Yang M, Liang Y, Xu J, Xu H, Nie Y . Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. J Inflamm Res. 2022; 15:1825-1844. PMC: 8928114. DOI: 10.2147/JIR.S353038. View

16.

Li X, Leonardi I, Putzel G, Semon A, Fiers W, Kusakabe T . Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature. 2022; 603(7902):672-678. PMC: 9166917. DOI: 10.1038/s41586-022-04502-w. View

17.

Shen Z, Luo W, Tan B, Nie K, Deng M, Wu S . Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn's disease. EBioMedicine. 2022; 85:104285. PMC: 9526137. DOI: 10.1016/j.ebiom.2022.104285. View

18.

Geervliet M, de Vries H, Jansen C, Rutten V, van Hees H, Wen C . Effects of Nissle 1917 on the Porcine Gut Microbiota, Intestinal Epithelium and Immune System in Early Life. Front Microbiol. 2022; 13:842437. PMC: 8914288. DOI: 10.3389/fmicb.2022.842437. View

19.

Schwerd T, Frivolt K, Clavel T, Lagkouvardos I, Katona G, Mayr D . Exclusive enteral nutrition in active pediatric Crohn disease: Effects on intestinal microbiota and immune regulation. J Allergy Clin Immunol. 2016; 138(2):592-6. DOI: 10.1016/j.jaci.2015.12.1331. View

20.

Crunkhorn S . Yeast probiotics treat IBD. Nat Rev Drug Discov. 2021; 20(8):588. DOI: 10.1038/d41573-021-00116-5. View